In patients with stage @ CKD , adjusted mean treatment differences versus placebo in changes from baseline in HbA@c at week @ were -@ % ( @ % CI -@ to -@ ) for empagliflozin @ mg and -@ % ( -@ to -@ ) for empagliflozin @ mg ( both p < @ ) .